论文部分内容阅读
目的:比较头孢哌酮-舒巴坦钠对慢性心衰伴肺部感染患者临床抗感染的疗效。方法:选取2014年3月—2016年3月间收治的慢性心力衰竭伴肺部感染患者92例,将其随机分为对照组和治疗组,每组46例;对照组患者给予舒巴坦治疗,治疗组患者给予头孢哌酮-舒巴坦复合制剂治疗,评价两组患者治疗后的总有效率、体温恢复正常时间和肺部感染症状消失时间等。结果:治疗组患者经治疗后慢性心力衰竭伴肺部感染疾病控制症状的疗效明显优于对照组(P<0.05);治疗期间不良反应的发生率低于对照组(P<0.05);体温恢复正常时间、肺部感染症状完全消失时间和住院时间明显短于对照组(P<0.05)。结论:采用头孢哌酮-舒巴坦复合制剂治疗慢性心力衰竭伴肺部感染患者的临床疗效较为显著。
Objective: To compare the curative effect of cefoperazone-sulbactam sodium on clinical anti-infection in patients with chronic heart failure and pulmonary infection. Methods: A total of 92 patients with chronic heart failure and pulmonary infection admitted to our hospital from March 2014 to March 2016 were randomly divided into control group and treatment group, with 46 patients in each group. Patients in the control group were treated with sulbactam The patients in the treatment group were given cefoperazone-sulbactam combination therapy. The total effective rate, the normal time of body temperature recovery and the disappearance of symptoms of pulmonary infection in both groups were evaluated. Results: The curative effect of treating patients with chronic heart failure and pulmonary infection after treatment was significantly better than that of control group (P <0.05). The incidence of adverse reactions in treatment group was lower than that in control group (P <0.05) Normal time, symptoms of pulmonary infection completely disappeared and hospitalization time was significantly shorter than the control group (P <0.05). Conclusion: The clinical efficacy of cefoperazone-sulbactam in the treatment of patients with chronic heart failure and pulmonary infection is significant.